

NCT02366819 comparison:

Summary:
CHIA has 24 criteria while your personal folder has 24 criteria
Total found criteria: 24/24
Total not Found: 0/24
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Histologically confirmed locally advanced gastric  │ Histologically confirmed locally advanced gastric  │
│ (primary endpoint includes proximal and mid-body   │ (primary endpoint includes proximal and mid-body   │
│ stomach) or esophagogastric adenocarcinoma; distal │ stomach) or esophagogastric adenocarcinoma; distal │
│ gastric (antral) adenocarcinomas are eligible for  │ gastric (antral) adenocarcinomas are eligible for  │
│ enrolment but will not be included in the primary  │ enrolment but will not be included in the primary  │
│ analysis                                           │ analysis                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Locally advanced disease as determined by          │ Locally advanced disease as determined by          │
│ endoscopic ultrasound (EUS) stage > primary tumor  │ endoscopic ultrasound (EUS) stage \> primary tumor │
│ (T) 3 and/or any T, lymph nodes (N)+ disease       │ (T) 3 and/or any T, lymph nodes (N)+ disease       │
│ without metastatic disease (Mx)                    │ without metastatic disease (Mx)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ All patients must have diagnostic laparoscopy with │ All patients must have diagnostic laparoscopy with │
│ diagnostic washings for cytology; both cytology    │ diagnostic washings for cytology; both cytology    │
│ positive and negative patients are eligible for    │ positive and negative patients are eligible for    │
│ enrolment, but only cytology negative patients     │ enrolment, but only cytology negative patients     │
│ will be included in the primary analyses; gross    │ will be included in the primary analyses; gross    │
│ peritoneal disease is not eligible                 │ peritoneal disease is not eligible                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │
│ performance status =< 1                            │ performance status =\< 1                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Eligible for surgery with curative intent          │ Eligible for surgery with curative intent          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute neutrophil count (ANC) >= 1250/ul         │ Absolute neutrophil count (ANC) \>= 1250/ul        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin >= 9 g/dL                               │ Hemoglobin \>= 9 g/dL                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelets >= 100,000/ul                            │ Platelets \>= 100,000/ul                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total bilirubin < 1.5 x upper limit of normal      │ Total bilirubin \< 1.5 x upper limit of normal     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum glutamic oxaloacetic transaminase (SGOT) and │ Serum glutamic oxaloacetic transaminase (SGOT) and │
│ serum glutamate pyruvate transaminase (SGPT) < 2.5 │ serum glutamate pyruvate transaminase (SGPT) \<    │
│ x upper limit of normal for patients without liver │ 2.5 x upper limit of normal for patients without   │
│ metastases OR SGOT and SGPT < 5 x upper limit of   │ liver metastases OR SGOT and SGPT \< 5 x upper     │
│ normal for patients with liver metastases          │ limit of normal for patients with liver metastases │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Creatinine =< 1.5 x upper limit of normal          │ Creatinine =\< 1.5 x upper limit of normal         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Measurable or non-measurable disease by Response   │ Measurable or non-measurable disease by Response   │
│ Evaluation Criteria in Solid Tumor (RECIST) 1.1    │ Evaluation Criteria in Solid Tumor (RECIST) 1.1    │
│ will be allowed                                    │ will be allowed                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of child-bearing potential and men must      │ Women of child-bearing potential and men must      │
│ agree to use adequate contraception (hormonal or   │ agree to use adequate contraception (hormonal or   │
│ barrier method of birth control; abstinence) prior │ barrier method of birth control; abstinence) prior │
│ to study entry and for the duration of study       │ to study entry and for the duration of study       │
│ participation, up until 30 days after final study  │ participation, up until 30 days after final study  │
│ treatment; should a woman become pregnant or       │ treatment; should a woman become pregnant or       │
│ suspect that she is pregnant while participating   │ suspect that she is pregnant while participating   │
│ in this study, she should inform her treating      │ in this study, she should inform her treating      │
│ physician immediately                              │ physician immediately                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients taking substrates, inhibitors, or         │ Patients taking substrates, inhibitors, or         │
│ inducers of cytochrome P450, family 3, subfamily   │ inducers of cytochrome P450, family 3, subfamily   │
│ A, polypeptide 4 (CYP3A4) should be encouraged to  │ A, polypeptide 4 (CYP3A4) should be encouraged to  │
│ switch to alternative drugs whenever possible,     │ switch to alternative drugs whenever possible,     │
│ given the potential for drug-drug interactions     │ given the potential for drug-drug interactions     │
│ with irinotecan                                    │ with irinotecan                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signed informed consent                            │ Signed informed consent                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous or concurrent malignancy, except for      │ Previous or concurrent malignancy, except for      │
│ adequately treated basal cell or squamous cell     │ adequately treated basal cell or squamous cell     │
│ skin cancer, in situ cervical cancer, or any other │ skin cancer, in situ cervical cancer, or any other │
│ cancer for which the patient has been previously   │ cancer for which the patient has been previously   │
│ treated and the lifetime recurrence risk is less   │ treated and the lifetime recurrence risk is less   │
│ than 30%                                           │ than 30%                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inflammatory bowel disease that is uncontrolled or │ Inflammatory bowel disease that is uncontrolled or │
│ on active treatment (Crohn's disease, ulcerative   │ on active treatment (Crohn's disease, ulcerative   │
│ colitis)                                           │ colitis)                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diarrhea, grade 1 or greater by the National       │ Diarrhea, grade 1 or greater by the National       │
│ Cancer Institute Common Terminology Criteria for   │ Cancer Institute Common Terminology Criteria for   │
│ Adverse Events (NCI-CTCAE, version [v] 4.0)        │ Adverse Events (NCI-CTCAE, version \[v\] 4.0)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0 │ Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serious underlying medical or psychiatric          │ Serious underlying medical or psychiatric          │
│ illnesses that would, in the opinion of the        │ illnesses that would, in the opinion of the        │
│ treating physician, substantially increase the     │ treating physician, substantially increase the     │
│ risk for complications related to treatment        │ risk for complications related to treatment        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active uncontrolled bleeding                       │ Active uncontrolled bleeding                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy or breastfeeding                         │ Pregnancy or breastfeeding                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major surgery within 4 weeks                       │ Major surgery within 4 weeks                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with any polymorphism in UGT1A1 other     │ Patients with any polymorphism in UGT1A1 other     │
│ than *1 or *28 (e.g, *6) will be allowed and       │ than \*1 or \*28 (e.g, \*6) will be allowed and    │
│ treated as in the *28/*28 dosing group             │ treated as in the \*28/\*28 dosing group           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛